PP242 is a potent and selective inhibitor of mTOR (mammalian target of rapamycin), targeting both mTORC1 and mTORC2 complexes. It is widely used in research to study signaling pathways involved in cell growth, proliferation, and survival. Due to its ability to block mTOR activity more completely than rapamycin, PP242 is valuable in cancer research, particularly in investigating tumor resistance mechanisms and the role of mTOR in metabolic regulation. It has shown promise in preclinical studies for suppressing the growth of various cancer cell lines, including those resistant to conventional therapies. PP242 is also used to explore autophagy induction, as mTOR inhibition triggers cellular self-degradation processes. Its application extends to immunology and neurodegenerative disease research, where mTOR pathway dysregulation plays a critical role. Because of its cell permeability and reversible action, PP242 is suitable for both in vitro and in vivo experimental models.